Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer
Standard
Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. / Lebok, Patrick; von Hassel, Aurelia; Meiners, Jan; Hube-Magg, Claudia; Simon, Ronald; Höflmayer, Doris; Hinsch, Andrea; Dum, David; Fraune, Christoph; Göbel, Cosima; Möller, Katharina; Sauter, Guido; Jacobsen, Frank; Büscheck, Franziska; Prien, Kristina; Krech, Till; Krech, Rainer Horst; von der Assen, Albert; Wölber, Linn; Witzel, Isabell; Schmalfeldt, Barbara; Geist, Stefan; Paluchoswski, Peter; Wilke, Christian; Heilenkötter, Uwe; Terracciano, Luigi; Müller, Volkmar; Wilczak, Waldemar; Burandt, Eike Christian.
in: AGING-US, Jahrgang 11, Nr. 18, 18.09.2019, S. 7796-7804.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer
AU - Lebok, Patrick
AU - von Hassel, Aurelia
AU - Meiners, Jan
AU - Hube-Magg, Claudia
AU - Simon, Ronald
AU - Höflmayer, Doris
AU - Hinsch, Andrea
AU - Dum, David
AU - Fraune, Christoph
AU - Göbel, Cosima
AU - Möller, Katharina
AU - Sauter, Guido
AU - Jacobsen, Frank
AU - Büscheck, Franziska
AU - Prien, Kristina
AU - Krech, Till
AU - Krech, Rainer Horst
AU - von der Assen, Albert
AU - Wölber, Linn
AU - Witzel, Isabell
AU - Schmalfeldt, Barbara
AU - Geist, Stefan
AU - Paluchoswski, Peter
AU - Wilke, Christian
AU - Heilenkötter, Uwe
AU - Terracciano, Luigi
AU - Müller, Volkmar
AU - Wilczak, Waldemar
AU - Burandt, Eike Christian
PY - 2019/9/18
Y1 - 2019/9/18
N2 - Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression in 2,197 breast cancers. LPCAT1 staining was found in 97.8% of 1,774 interpretable tumors, including 48.1% with weak, 28.7% with moderate, and 14.4% with strong expression. The frequency of LPCAT1 positivity depended on the histological tumor type. Moderate or strong LPCAT1 positivity was more common in cancers of no special type (NST) (46.2%) than in lobular carcinomas (25.9%; p<0.0001). Strong LPCAT1 was associated with BRE grade, tumor cell proliferation and overall survival in all cancers and in the subgroup of NST cancers (p<0.0001, each). In the subset of NST cancers the prognostic effect of LPCAT1 expression was independent of pT, and BRE grade (p<0.0001 each). A comparison with molecular features showed that LPCAT1 was strongly associated with estrogen receptor negativity (p<0.0001), progesterone receptor negativity (p<0,0001), amplification of HER2 (p<0.0001) and MYC (p=0.0066), as well as deletions of PTEN (p<0.0001) and CDKNA2 (p=0.0151). It is concluded that LPCAT1 overexpression is linked to adverse tumor features and poor prognosis in breast cancer. These data also highlight the important role of lipid metabolism in breast cancer biology.
AB - Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression in 2,197 breast cancers. LPCAT1 staining was found in 97.8% of 1,774 interpretable tumors, including 48.1% with weak, 28.7% with moderate, and 14.4% with strong expression. The frequency of LPCAT1 positivity depended on the histological tumor type. Moderate or strong LPCAT1 positivity was more common in cancers of no special type (NST) (46.2%) than in lobular carcinomas (25.9%; p<0.0001). Strong LPCAT1 was associated with BRE grade, tumor cell proliferation and overall survival in all cancers and in the subgroup of NST cancers (p<0.0001, each). In the subset of NST cancers the prognostic effect of LPCAT1 expression was independent of pT, and BRE grade (p<0.0001 each). A comparison with molecular features showed that LPCAT1 was strongly associated with estrogen receptor negativity (p<0.0001), progesterone receptor negativity (p<0,0001), amplification of HER2 (p<0.0001) and MYC (p=0.0066), as well as deletions of PTEN (p<0.0001) and CDKNA2 (p=0.0151). It is concluded that LPCAT1 overexpression is linked to adverse tumor features and poor prognosis in breast cancer. These data also highlight the important role of lipid metabolism in breast cancer biology.
U2 - 10.18632/aging.102287
DO - 10.18632/aging.102287
M3 - SCORING: Journal article
C2 - 31533087
VL - 11
SP - 7796
EP - 7804
JO - AGING-US
JF - AGING-US
SN - 1945-4589
IS - 18
ER -